NasdaqCM - Delayed Quote • USD
Cue Biopharma, Inc. (CUE)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:28 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.28 | -0.27 | -1.03 | -1 |
| Low Estimate | -0.32 | -0.34 | -1.33 | -1.83 |
| High Estimate | -0.24 | -0.21 | -0.67 | -0.46 |
| Year Ago EPS | -0.29 | -0.29 | -1.11 | -1.03 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 1.21M | 1.28M | 9.01M | 15.73M |
| Low Estimate | 200k | 200k | 4M | 4M |
| High Estimate | 1.95M | 2.2M | 15.8M | 45M |
| Year Ago Sales | 187k | -- | 5.49M | 9.01M |
| Sales Growth (year/est) | 547.10% | -- | 64.10% | 74.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.3 | -0.34 | -0.28 |
| EPS Actual | -0.29 | -0.29 | -0.24 | -0.29 |
| Difference | 0 | 0.01 | 0.1 | -0.01 |
| Surprise % | 0.00% | 3.30% | 29.40% | -3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.28 | -0.27 | -1.03 | -1 |
| 7 Days Ago | -0.28 | -0.27 | -1.03 | -1 |
| 30 Days Ago | -0.27 | -0.29 | -1.11 | -0.97 |
| 60 Days Ago | -0.26 | -0.28 | -1.09 | -0.98 |
| 90 Days Ago | -0.26 | -0.28 | -1.09 | -0.98 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CUE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 3.40% | -- | -- | 6.50% |
| Next Qtr. | 6.90% | -- | -- | 12.00% |
| Current Year | 7.20% | -- | -- | 5.30% |
| Next Year | 2.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Stifel: Buy to Buy | 4/9/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/9/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 4/3/2024 |
| Initiated | Jefferies: Buy | 3/13/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/6/2023 |
| Reiterates | Stifel: Buy to Buy | 6/15/2023 |
Related Tickers
TFFP TFF Pharmaceuticals, Inc.
2.9215
-5.45%
APTO Aptose Biosciences Inc.
1.2200
+5.17%
CGTX Cognition Therapeutics, Inc.
1.9500
0.00%
COYA Coya Therapeutics, Inc.
8.60
+2.02%
KRON Kronos Bio, Inc.
1.0000
+2.04%
INAB IN8bio, Inc.
1.0400
0.00%
ALRN Aileron Therapeutics, Inc.
5.0000
-1.19%
TRVI Trevi Therapeutics, Inc.
2.7800
+9.45%
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
OCUP Ocuphire Pharma, Inc.
1.6100
+4.89%